Inventiva S.A. (NASDAQ:IVA) Short Interest Down 9.2% in November

Inventiva S.A. (NASDAQ:IVA) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 390,300 shares, a decrease of 9.2% from the October 31st total of 429,900 shares. Based on an average daily volume of 207,600 shares, the short-interest ratio is presently 1.9 days.

Inventiva Stock Up 1.1 %

Shares of NASDAQ:IVA opened at $2.68 on Tuesday. The company has a 50 day moving average price of $2.43 and a two-hundred day moving average price of $2.61. Inventiva has a 52 week low of $1.53 and a 52 week high of $4.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IVA shares. Stifel Nicolaus dropped their price target on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. UBS Group assumed coverage on shares of Inventiva in a report on Tuesday, November 12th. They set a “neutral” rating and a $3.00 target price for the company. Finally, HC Wainwright reduced their price target on Inventiva from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.25.

Institutional Trading of Inventiva

An institutional investor recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.